The Consolidated Appropriations Act of 2026 (CAA 2026) introduces some of the most significant federal changes to Pharmacy Benefit Manager (PBM) oversight over the past two decades. The PBM portion of the new law focuses on transparency, rebate pass-through, and fiduciary accountability under the Employee Retirement Income Security Act of 1974 (ERISA). It also reflects broader federal and state efforts to increase transparency of PBM practices. Together, these changes reshape how plan sponsors report, evaluate, and govern pharmacy benefits.
The CAA 2026 is now signed into law, but timing impact on pharmacy plans depends on the plan’s effective date. Requirements generally must be implemented within 30 months of February 3, 2026, which means calendar-year plans would need to comply by January 1, 2029.
What the Law Requires
The CAA 2026 introduces four core pharmacy provisions affecting group health plans:
Mandatory Reporting and Standardized Transparency
PBMs must provide semiannual reports to plan sponsors and provide quarterly reports upon request. These reports must include standardized, plan-level data. Specifically, they must cover pharmacy spend, drug utilization, and financial flows. In addition, PBMs must provide participant-facing summary documents. Non-compliance carries penalties of up to $10,000 per day.
This provision changes the information dynamic between plan sponsors and PBMs. Historically, plan sponsors had limited visibility into rebate flows, pricing mechanics, and PBM margins. Now, they can treat data access as a baseline expectation, not a negotiated privilege.
100% Pass-Through of Rebates and Manufacturer Compensation
The CAA 2026 will require PBMs to pass through 100% of rebates, fees, discounts, and all other manufacturer remuneration to plan sponsors, on at least a quarterly basis.
This creates a structural shift in PBM economics. Under the new law, rebate retention and spread pricing become less viable. As a result, PBMs will likely move toward transparent, fee-based compensation structures.
However, plan sponsors and brokers should not assume automatic savings. PBMs may shift margin into administrative fees, formulary strategies, or network arrangements. Therefore, plan sponsors may need to revisit contract terms and strengthen performance monitoring to capture financial benefit.
Expanded ERISA Fiduciary Accountability
The CAA 2026 brings PBM arrangements under ERISA fiduciary scrutiny. Non-compliant contracts may constitute prohibited transactions. As a result, plan fiduciaries must ensure reasonable compensation and transparent financial arrangements. They must also actively oversee vendor relationships.
Pharmacy benefits now carry the same standard as retirement plan investments and fees. This change creates compliance and litigation risk. Plan sponsors can reduce that risk by documenting vendor selection, contracting, and ongoing monitoring.
Full Disclosure of All Vendor Compensation
Beyond rebates, the CAA requires full disclosure of vendor compensation. PBMs, third-party administrators, and other service providers must disclose direct and indirect compensation. This includes administrative fees, performance incentives, and indirect revenue streams.
For the first time, plan sponsors have a regulatory basis for reviewing the full compensation ecosystem.
What This Means for Plan Sponsors and Brokers
Greater transparency does not automatically reduce pharmacy costs. However, the CAA may create conditions for pharmacy benefit savings by giving plan sponsors access to more standardized PBM reporting on pharmacy spend, rebate flows, and vendor compensation. The value of this information depends on whether plan sponsors can interpret, validate, and act on it. Otherwise, PBM margin may simply shift to new areas.
Four priorities should be on every plan sponsor’s near-term agenda:
- Review and renegotiate PBM contracts. Many agreements reflect older economic assumptions. Identify provisions that conflict with pass-through requirements. Then reassess pricing structures, guarantees, and renewal timing. Independent market checks can help clarify where terms may need to change.
- Confirm audit rights and independent validation are in place. PBM-reported data only creates value when plan sponsors can verify it. Through rebate reconciliation, claims validation, and independent monitoring, Truveris supports plans in ensuring PBM data is accurate.
- Integrate pharmacy into fiduciary governance. Pharmacy benefits should sit alongside retirement benefits in ERISA fiduciary committees. Plans need to document vendor selection, oversight activities, and corrective actions and justify selection. Independence will be critical in pharmacy partners.
- Translate requirements into action for clients. Work with a pharmacy expert partner like Truveris that assess the health of PBM contracts, identifies renegotiation opportunities, and supports fiduciary requirements.
As plan sponsors and brokers navigate these changes, the focus will shift from accessing PBM data to interpreting and validating it. Truveris supports this shift through 100% claim-by-claim review to ensure PBM accountability and reporting accuracy, helping ensure that transparency translates into measurable outcomes. These capabilities are becoming increasingly important as fiduciary expectations continue to evolve.
Frequently Asked Questions
Does pass-through mean plan sponsors will automatically pay less for drugs?
Not necessarily. With the CAA 2026 law, rebates must flow directly to the plan. However, PBMs may shift margin to administrative fees or formulary design. Actual savings depend on active contract renegotiation and monitoring.
What are the fiduciary risks if plan sponsors do nothing?
Under CAA 2026, non-compliant PBM contracts may constitute prohibited transactions under ERISA. Plan fiduciaries face higher regulatory and litigation exposure without active oversight. Therefore, documented diligence matters more than passive reliance on PBM reporting. Working with Truveris to support PBM oversight and hold PBMs accountable can support the fiduciary requirements of plan sponsors.
What should brokers do now on behalf of clients?
Partner with Truveris and start with a CAA-focused contract review focused on pass-through compliance, pricing structures, and audit rights. Then assess whether current oversight can validate PBM-reported data. Finally, help clients understand pharmacy benefits now carry fiduciary weight.
